Bristol-Myers Squibb employees ride across the U.S. to raise money to support cancer research by Stand Up To Cancer

Bristol-Myers SquibbThe first of seven teams of Bristol-Myers Squibb (NYSE:BMY) employees mounted their bikes in Cannon Beach, OR, today to kick off the 2017 Coast 2 Coast 4 Cancer Ride. Ninety-three novice riders will bike a total of nearly 2,800 miles during the 21-day mission to raise money and awareness for Stand Up To Cancer’s innovative cancer research programs that bring together collaborative teams of scientific researchers to help get new therapies to patients faster.

Bristol-Myers Squibb will match funds raised during the 2017 Coast 2 Coast 4 Cancer Ride dollar-for-dollar up to a total of $500,000. This is the fourth Coast 2 Coast 4 Cancer Ride benefitting Stand Up To Cancer (SU2C). Last year’s Coast 2 Coast 4 Cancer ride raised over $1 million for SU2C research programs.

Katie Couric, award-winning journalist and SU2C co-founder said, "All of us at Stand Up To Cancer are profoundly grateful to the Bristol-Myers Squibb employees as they cycle cross-country. Their commitment honors those who are fighting cancer, as well as those lost to the disease. The riders - and everyone who supports them - are helping SU2C advance research with the hope of one day turning more and more cancer patients into long-term survivors."

This year, Bonni Norwood of Spring Lakes, MI, a cancer survivor herself who hasn’t ridden a bike in 45 years, will ride from Kansas City, MO, to Indianapolis, IN. "While training to ride 75 miles per day is difficult for me, my struggles pale in comparison to those faced by people fighting cancer," said Bonni. "I'm riding for two dear friends who are both young and vibrant, but are currently battling cancer. When I face steep climbs or cross winds, I will dig deep and persevere for them and for all cancer patients."

"Every day, we, at Bristol-Myers Squibb, challenge ourselves individually and collectively as a team to fight cancer," said Teresa Bitetti, senior vice president, U.S. Oncology, Bristol-Myers Squibb. "Our employees who are riding across the country exemplify this passion and purpose - to help drive real change for people impacted by cancer."

Concurrently, seventy-eight Bristol-Myers Squibb employees in Europe will embark on a Country 2 Country 4 Cancer Ride . The Country 2 Country Ride kicks off September 8 in Germany, and spans 3,600 kilometers (2,236 miles) through Switzerland, Italy, France, Spain, and the United Kingdom. Funds raised will support one of eight market-specific cancer-focused charities in Europe.

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

About Stand Up To Cancer
Stand Up To Cancer (SU2C) raises funds to accelerate the pace of research to get new therapies to patients quickly and save lives now. SU2C, a division of the Entertainment Industry Foundation (EIF), a 501(c)(3) charitable organization, was established in 2008 by film and media leaders who utilize the industry’s resources to engage the public in supporting a new, collaborative model of cancer research, and to increase awareness about cancer prevention as well as progress being made in the fight against the disease. As SU2C's scientific partner, the American Association for Cancer Research (AACR) and a Scientific Advisory Committee led by Nobel Laureate Phillip A. Sharp, PhD, conduct rigorous, competitive review processes to identify the best research proposals to recommend for funding, oversee grants administration, and provide expert review of research progress.

Current members of the SU2C Council of Founders and Advisors (CFA) include Katie Couric, Sherry Lansing, Lisa Paulsen, Rusty Robertson, Sue Schwartz, Pamela Oas Williams, Ellen Ziffren, and Kathleen Lobb. The late Laura Ziskin and the late Noreen Fraser are also co-founders. Sung Poblete, PhD, RN, has served as SU2C’s president and CEO since 2011.

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

Cells of 3 advanced cancers die with drug-like com…

Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggres...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]